Table 2.
Past chemotherapy history.
| Characteristic | N | Platinum sensitive N = 116 (60%)1 |
Platinum resistant N = 76 (40%)1 |
p-value2 |
|---|---|---|---|---|
| 1st line | 190 | 115 | 75 | >0.99 |
| Missing | 1 | 1 | ||
| 1st line (type) | 186 | 0.30 | ||
| Platinum based | 100 (88%) | 61 (84%) | ||
| Bevacizumab + CT | 11 (9.7%) | 12 (16%) | ||
| Other | 2 (1.8%) | 0 (0%) | ||
| Missing | 3 | 3 | ||
| 2nd line | 187 | 94 (82%) | 65 (89%) | 0.22 |
| Missing | 2 | 3 | ||
| 2nd line (type) | 182 | 0.009 | ||
| Platinum based | 43 (38%) | 17 (24%) | ||
| Bevacizumab + CT | 37 (33%) | 27 (39%) | ||
| Other | 12 (11%) | 19 (27%) | ||
| No CT | 20 (18%) | 7 (10%) | ||
| Missing | 4 | 6 | ||
| 3rd line | 180 | 60 (55%) | 42 (60%) | 0.47 |
| Missing | 6 | 6 | ||
| 3rd line (type) | 178 | 0.23 | ||
| Platinum based | 16 (15%) | 9 (13%) | ||
| Bevacizumab + CT | 11 (10%) | 6 (8.6%) | ||
| Other | 26 (24%) | 27 (39%) | ||
| No CT | 55 (51%) | 28 (40%) | ||
| Missing | 8 | 6 | ||
| Systemic chemotherapy (cycles) | 123 | 14 (8, 20) | 13 (10, 18) | 0.70 |
| Missing | 46 | 23 | ||
| PARPi (before PIPAC) | 159 | 10 (11%) | 5 (7.8%) | 0.57 |
| Missing | 21 | 12 | ||
| Bidirectional chemotherapy (IV-IP) | 127 | 27 (34%) | 28 (58%) | 0.008 |
| Missing | 37 | 28 |
1 n (%); Median (IQR).
2 Fisher's exact test; Pearson's Chi-squared test; Wilcoxon rank sum test.
CT, platinum based or other chemotherapy; PARPi, poly ADP ribose polymerase inhibitor.